UPDATE: Canaccord Genuity Raises PT to $10 on Synergy Pharmaceuticals on Positive Plecanatide Data

Canaccord Genuity reiterated its Buy rating on Synergy Pharmaceuticals SGYP and increased its price target from $7 to $10. Canaccord Genuity noted, "Reiterate BUY, raise target to $10 on increased probability of success for plecanatide in CIC. We see clear unmet need in chronic constipation (CIC) patients who don't respond/have AEs on current therapies. Compared to Linzess (FRX/IRWD), plecanatide may have better tolerability (no diarrhea in Phase 2a). We are raising our pNPV based target to $10 from $7, driven by increased chance of plecanatide success on today's positive proof of concept data." Synergy Pharmaceuticals closed at $5.26 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetIntraday UpdateAnalyst RatingsCanaccord Genuity
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!